Yao Jie An Kang-B (02617) published exploratory clinical results in the sub-journal of Nature magazine on the core product Tuo Enguo Tini as a single drug and in combination with Atezolizumab to treat advanced solid tumors.

Smart finance and economics APP news, YaoJieAnKang-B (02617) announced that they have published in Nature Communications (IF=15.7) the exploratory clinical results of the core product tigaertinib alone and in combination with atezolizumab for the treatment of advanced solid tumors.